Nefarious Nefazodone And Flashy Rare Side Effects

A sharp psychopharmacology + decision-theory essay. Nefazodone is a good antidepressant lacking SSRIs' common sexual/emotional side effects, but has a rare (1/300,000) fatal liver failure — so it's essentially banned/unused while SSRIs' diffuse-but-common harms (10M ruined sex lives) are tolerated (QALY math: SSRIs cost 1.5M QALYs vs nefazodone's 5,000). Same pattern with modafinil (rare SJS) vs Adderall. The key twist: Seroquel actually causes MORE deaths (1/20,000) than nefazodone but is the 6th-best-selling US drug — because Seroquel deaths are statistically diffuse/unattributable while nefazodone deaths are identifiable (media + lawsuits). Doctors avoid identifiable-risk drugs (lawsuit-safety, not patient-safety); a critique of lawsuits as a de facto regulatory mechanism.

Quality 71 · Strong. 71 — high Strong. A genuinely generative essay; the flashy-rare-vs-diffuse-common side-effect asymmetry and the identifiable-vs-statistical-death insight (Seroquel kills more than nefazodone yet is preferred) + the lawsuit/principal-agent analysis are memorable and illuminating. Held at high-Strong given the epistemic-status disclaimer and the topical drug specifics.

Claude’s paradigm shift 56 · Moderate. 56 — Notable. The flashy-rare-side-effect / identifiable-vs-statistical-death asymmetry + lawsuit-driven-underprescription framing is a fresh, generative synthesis.

Real-world impact 2 · Minor. 2 — minor/within-blog. A pointed critique of medical risk-perception and lawsuit-regulation; discourse-level, no material change.